Oral GLP-1 therapy is bringing obesity treatment to millions of patients who had never used weight-loss medicines before
The obesity treatment landscape is changing at remarkable speed, and Novo Nordisk has just added another milestone to the story.
The Danish pharmaceutical giant announced that Wegovy® (semaglutide) tablets 25 mg have surpassed 3 million prescriptions in the United States within just over five months of launch, making it one of the strongest pharmaceutical product launches by prescription volume in recent U.S. history.
The achievement highlights not only the growing demand for obesity medicines but also the increasing acceptance of oral GLP-1 therapies among patients and healthcare providers.
A Prescription Every Five Seconds
According to Novo Nordisk, the oral version of Wegovy reached the 3-million-prescription mark after becoming available in January 2026. The company estimates that this volume translates to approximately one prescription being filled every five seconds across the United States.
The growth trajectory has been particularly striking. The first million prescriptions were achieved within about 12 weeks of launch. The next two million prescriptions accumulated even faster, taking only another 10 weeks. Such acceleration suggests that awareness, physician confidence, and patient adoption have all increased rapidly since launch.
For an industry accustomed to gradual product adoption curves, these numbers represent an exceptional commercial performance.
Expanding the Market, Not Just Shifting Patients
Perhaps the most significant insight from Novo Nordisk's data is that the majority of users are new to GLP-1 therapy.
The company reported that more than 80% of new Wegovy pill prescriptions were written for patients who had not previously used GLP-1 medicines.
This finding suggests that oral semaglutide is not merely replacing injectable obesity treatments. Instead, it appears to be expanding the overall treatment market by attracting patients who may have been hesitant to start injectable therapies.
For years, injectable administration has been viewed as a barrier for some patients seeking obesity treatment. An effective oral alternative may help overcome psychological and practical concerns associated with injections, allowing a broader patient population to access evidence-based obesity care.
Why Oral GLP-1 Therapy Matters
The emergence of oral GLP-1 therapies represents one of the most important developments in obesity medicine.
GLP-1 receptor agonists have transformed the treatment of obesity and diabetes over the past decade. However, most blockbuster products in this category have required injections.
By introducing a tablet formulation, Novo Nordisk has potentially unlocked access for millions of patients who prefer oral medications. The company's data indicate that this strategy is resonating strongly with healthcare providers and patients alike.
The success of Wegovy tablets may also influence future development strategies across the pharmaceutical industry, encouraging competitors to invest more heavily in oral peptide technologies.
A Competitive Edge Beyond Weight Loss
Novo Nordisk continues to position Wegovy as more than a weight-management medicine.
According to the company, Wegovy is approved for weight reduction when combined with diet and exercise, and it is also approved to reduce the risk of major cardiovascular events—including heart attack, stroke, and cardiovascular death—in eligible adults with obesity and established heart disease.
This cardiovascular benefit differentiates Wegovy from many traditional weight-loss treatments and has become a major factor driving physician adoption.
Jamey Millar, Executive Vice President of U.S. Operations at Novo Nordisk, emphasized that the company now offers multiple Wegovy options, allowing healthcare providers and patients to choose the formulation that best suits their needs.
Wegovy HD Adds Momentum
The oral tablet milestone comes at a time when Novo Nordisk is also expanding its obesity portfolio.
The company recently introduced Wegovy® HD (semaglutide) injection 7.2 mg, and early uptake has reportedly been strong. Together, the tablet and high-dose injectable formulations are helping Novo Nordisk strengthen its leadership position in the rapidly growing obesity market.
With multiple dosage forms available, the company is building what could become one of the most comprehensive obesity treatment portfolios in the industry.
The Access Challenge
Despite scientific advances, affordability and access remain major concerns in obesity care.
Novo Nordisk says it is working to improve patient access through several initiatives. Commercially insured patients may be eligible to obtain Wegovy for as little as $25 per month through savings programs, while a newly announced Medicare GLP-1 Bridge initiative is expected to provide eligible Medicare beneficiaries access to Wegovy tablets and injections for a monthly copay of $50 beginning July 2026.
The medicine is also available through more than 70,000 U.S. pharmacies, telehealth providers, and NovoCare Pharmacy.
As policymakers, insurers, and healthcare systems continue debating obesity treatment coverage, access programs are likely to remain a key battleground in the GLP-1 market.
Spotlight at ADA 2026
Novo Nordisk timed the announcement to coincide with the American Diabetes Association (ADA) 2026 Scientific Sessions in New Orleans, where the company is presenting multiple analyses involving Wegovy in adults with obesity. American Diabetes Association
The event provides an important platform for showcasing both commercial success and emerging clinical evidence, reinforcing Novo Nordisk's leadership in metabolic disease research.
Looking Beyond the United States
While the United States remains the first market for oral Wegovy, Novo Nordisk has already begun preparing for international expansion.
The company plans to launch the product in additional markets during the second half of 2026 and has already announced approval and launch activities in the United Arab Emirates.
Global rollout could significantly increase the medicine's impact, particularly as obesity prevalence continues to rise worldwide.
The Bigger Picture
The 3-million-prescription milestone is more than a commercial success story.
It signals a broader shift in how obesity is being treated and perceived. Historically, obesity therapies struggled with limited effectiveness, poor adherence, and social stigma. The rapid adoption of Wegovy tablets suggests a growing willingness among patients and healthcare professionals to view obesity as a chronic disease requiring medical treatment.
For Novo Nordisk, the numbers reinforce its position at the center of one of healthcare's fastest-growing therapeutic categories.
For patients, the success of an oral GLP-1 option may represent something even more important: easier access to treatment without the barrier of injections.
As obesity rates continue to rise globally, the remarkable launch of Wegovy tablets may be remembered as a turning point—one that brought modern obesity therapy to millions who previously remained untreated.
